Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(43%)
Results Posted
33%(1 trials)

Phase Distribution

Ph early_phase_1
1
14%
Ph phase_2
4
57%
Ph phase_1
1
14%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 24 (66.7%)

Trials by Status

active_not_recruiting229%
withdrawn114%
completed343%
recruiting114%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_2

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

NCT07486830
completedphase_2

The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial

NCT05650645
active_not_recruitingearly_phase_1

A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles

NCT02019004
active_not_recruitingphase_1

Clinical Effects of Incobotulinum Toxin vs Corticosteroid in Plantar Fascitis

NCT06788158
completed

Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis

NCT04265092
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07486830Phase 2

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

Recruiting
NCT05650645Phase 2

The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial

Completed
NCT02019004Early Phase 1

A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles

Active Not Recruiting
NCT06788158Phase 1

Clinical Effects of Incobotulinum Toxin vs Corticosteroid in Plantar Fascitis

Active Not Recruiting
NCT04265092

Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis

Completed
NCT01653132Phase 2

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Completed
NCT01565395Phase 2

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7